Health ❯ Healthcare ❯ Clinical Trials

Phase III Trials

MATTERHORN Trial DESTINY-Breast05 Trial ASPEN Trial KOMET Trial Patient Outcomes Giredestrant Trials Efficacy Studies Interlace Trial Induction Chemotherapy AMPLITUDE Study

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

The approach starts immunotherapy before a chemoembolization procedure to help keep tumors in check earlier.

FDA Clears Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

FDA Approves First All-Oral, Fixed-Duration First-Line CLL/SLL Regimen: Calquence Plus Venetoclax

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Sobi to Acquire Arthrosi in Up to $1.5 Billion Deal to Bolster Gout Portfolio

Lancet Phase III Trial Finds Proton Therapy Improves 5-Year Survival in Oropharyngeal Cancer

Trial Finds Some Early Breast Cancer Patients Can Skip Sentinel Node Biopsy Without Harming 5-Year Control

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

FDA Approves One-Time Intrathecal Gene Therapy Itvisma for Older SMA Patients

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

FDA Approves Koselugo for Adults With NF1-Related Plexiform Neurofibromas

Roche Says Breast Cancer Pill Cuts Recurrence in Phase 3 Adjuvant Trial

FDA Approves Komzifti, First Menin Inhibitor for Relapsed NPM1‑Mutant AML